FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W201280849> ?p ?o ?g. }

• W201280849 abstract "The effect of granulocyte colony-stimulating factor (G-CSF) on neutropenia, infection, and cytotoxic chemotherapy administration was studied in a randomized trial in patients receiving intensive weekly chemotherapy for non-Hodgkinxybs lymphoma (NHL). Eighty patients (aged 16 to 71 years) with high-grade NHL (Kiel) of any stage were randomized to receive VAPEC-B chemotherapy alone (39 patients) or with G-CSF administered as a daily subcutaneous dose of 230 micrograms/m2 (41 patients). Prophylactic ketoconazole and cotrimoxazole were administered to all patients throughout treatment. The protocol specified identical dose modification and antibiotic treatment criteria bor both groups. Neutropenia (absolute neutrophil count [ANC] less than 1.0 x 10(9)/L) occurred in 15 of 41 (37%) of the G-CSF-treated patients and in 33 of 39 (85%) of the controls, giving a relative risk for control patients of 2.31 (95% confidence interval [CI], [1.51, 3.54]; P = .00001). Fever (greater than or equal to 37.5 degrees C) with neutropenia (ANC less than 1.0 x 10(9)/L) occurred in 9 of 41 (22%) of the G-CSF group and in 17 of 39 (44%) of the controls (relative risk for control, 2.26; 95% CI [1.01, 5.06]; P = .04). There were fewer treatment delays, with shorter duration (P = .01) in patients receiving G-CSF. Chemotherapy doses were reduced in 4 of 41 (10%) of the G-CSF patients and 13 of 39 (33%) of the controls (P = .01). The dose intensity of cytotoxic chemotherapy was significantly increased in patients receiving G-CSF (median of 95% in G-CSF group compared with 83% in control patients). Three vascular deaths occurred in the G-CSF group. Delays in the control group most commonly resulted from neutropenia (19 patients, compared with 2 patients in the G-CSF-treated group, P = .000007). Severe mucositis was the major dose-limiting toxicity in G-CSF-treated patients, but did not occur more frequently than in controls (15 patients in each group). Overall, patients randomized to receive G-CSF achieved a greater dose intensity than control patients, but this did not result in significant differences in drug toxicity (other than neutropenia), intravenous antibiotic usage, or hospitalization between the two groups." @default.
• W201280849 created "2016-06-24" @default.
• W201280849 creator A5006878292 @default.
• W201280849 creator A5009867179 @default.
• W201280849 creator A5011398209 @default.
• W201280849 creator A5017630825 @default.
• W201280849 creator A5020582543 @default.
• W201280849 creator A5024120918 @default.
• W201280849 creator A5041526616 @default.
• W201280849 creator A5051999451 @default.
• W201280849 creator A5080853957 @default.
• W201280849 date "1992-09-15" @default.
• W201280849 modified "2023-09-26" @default.
• W201280849 title "Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial" @default.
• W201280849 cites W136355804 @default.
• W201280849 cites W1537855173 @default.
• W201280849 cites W1547236510 @default.
• W201280849 cites W1547869235 @default.
• W201280849 cites W184894832 @default.
• W201280849 cites W1969369083 @default.
• W201280849 cites W1979300931 @default.
• W201280849 cites W1987951694 @default.
• W201280849 cites W1988104415 @default.
• W201280849 cites W1993880501 @default.
• W201280849 cites W1997217004 @default.
• W201280849 cites W2013254767 @default.
• W201280849 cites W2065910438 @default.
• W201280849 cites W2074454485 @default.
• W201280849 cites W2075876517 @default.
• W201280849 cites W2083022489 @default.
• W201280849 cites W2092368843 @default.
• W201280849 cites W2096104385 @default.
• W201280849 cites W2135729119 @default.
• W201280849 cites W2164470216 @default.
• W201280849 cites W2253102682 @default.
• W201280849 cites W2338649218 @default.
• W201280849 cites W2341557816 @default.
• W201280849 cites W2343432909 @default.
• W201280849 cites W2395321879 @default.
• W201280849 doi "https://doi.org/10.1182/blood.v80.6.1430.bloodjournal8061430" @default.
• W201280849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1381626" @default.
• W201280849 hasPublicationYear "1992" @default.
• W201280849 type Work @default.
• W201280849 sameAs 201280849 @default.
• W201280849 citedByCount "193" @default.
• W201280849 countsByYear W2012808492013 @default.
• W201280849 countsByYear W2012808492015 @default.
• W201280849 countsByYear W2012808492016 @default.
• W201280849 countsByYear W2012808492017 @default.
• W201280849 countsByYear W2012808492018 @default.
• W201280849 countsByYear W2012808492019 @default.
• W201280849 countsByYear W2012808492021 @default.
• W201280849 countsByYear W2012808492022 @default.
• W201280849 crossrefType "journal-article" @default.
• W201280849 hasAuthorship W201280849A5006878292 @default.
• W201280849 hasAuthorship W201280849A5009867179 @default.
• W201280849 hasAuthorship W201280849A5011398209 @default.
• W201280849 hasAuthorship W201280849A5017630825 @default.
• W201280849 hasAuthorship W201280849A5020582543 @default.
• W201280849 hasAuthorship W201280849A5024120918 @default.
• W201280849 hasAuthorship W201280849A5041526616 @default.
• W201280849 hasAuthorship W201280849A5051999451 @default.
• W201280849 hasAuthorship W201280849A5080853957 @default.
• W201280849 hasBestOaLocation W2012808491 @default.
• W201280849 hasConcept C126322002 @default.
• W201280849 hasConcept C141071460 @default.
• W201280849 hasConcept C168563851 @default.
• W201280849 hasConcept C2776694085 @default.
• W201280849 hasConcept C2777063308 @default.
• W201280849 hasConcept C2777767877 @default.
• W201280849 hasConcept C2778336483 @default.
• W201280849 hasConcept C2779338263 @default.
• W201280849 hasConcept C2781413609 @default.
• W201280849 hasConcept C71924100 @default.
• W201280849 hasConcept C74133956 @default.
• W201280849 hasConcept C90924648 @default.
• W201280849 hasConceptScore W201280849C126322002 @default.
• W201280849 hasConceptScore W201280849C141071460 @default.
• W201280849 hasConceptScore W201280849C168563851 @default.
• W201280849 hasConceptScore W201280849C2776694085 @default.
• W201280849 hasConceptScore W201280849C2777063308 @default.
• W201280849 hasConceptScore W201280849C2777767877 @default.
• W201280849 hasConceptScore W201280849C2778336483 @default.
• W201280849 hasConceptScore W201280849C2779338263 @default.
• W201280849 hasConceptScore W201280849C2781413609 @default.
• W201280849 hasConceptScore W201280849C71924100 @default.
• W201280849 hasConceptScore W201280849C74133956 @default.
• W201280849 hasConceptScore W201280849C90924648 @default.
• W201280849 hasLocation W2012808491 @default.
• W201280849 hasOpenAccess W201280849 @default.
• W201280849 hasPrimaryLocation W2012808491 @default.
• W201280849 hasRelatedWork W1524381114 @default.
• W201280849 hasRelatedWork W1529388857 @default.
• W201280849 hasRelatedWork W1794992355 @default.
• W201280849 hasRelatedWork W1907938184 @default.
• W201280849 hasRelatedWork W1933587402 @default.
• W201280849 hasRelatedWork W1987951694 @default.
• W201280849 hasRelatedWork W2017416417 @default.
• W201280849 hasRelatedWork W2024933507 @default.
• W201280849 hasRelatedWork W2074454485 @default.

• next